Voriconazole-induced Periostitis Following Lung Transplantation: Case Series

Q4 Medicine
Gouji Toyokawa , Miho Yamaguchi , Takafumi Yamaya , Mitsuaki Kawashima , Chihiro Konoeda , Koh Okamoto , Masaaki Sato
{"title":"Voriconazole-induced Periostitis Following Lung Transplantation: Case Series","authors":"Gouji Toyokawa ,&nbsp;Miho Yamaguchi ,&nbsp;Takafumi Yamaya ,&nbsp;Mitsuaki Kawashima ,&nbsp;Chihiro Konoeda ,&nbsp;Koh Okamoto ,&nbsp;Masaaki Sato","doi":"10.1016/j.tpr.2025.100179","DOIUrl":null,"url":null,"abstract":"<div><div>Voriconazole, the first-choice treatment for invasive aspergillosis, can induce periostitis. For unknown reasons, most reports on this rare side effect are in the field of organ transplantation, especially lung transplantation, and mostly from Western countries. However, in Asian countries, including Japan, the incidence of this complication may be underestimated. Herein, we report three Japanese patients who developed voriconazole-induced periostitis after lung transplantation. The patients’ initial symptoms were pain in the left shoulder, bilateral axillae, and left upper arm. The duration of voriconazole treatment before symptom onset ranged from 5 to 59 months. The diagnosis was confirmed by bone scintigraphy in two patients and computed tomography scan in one patient with or without elevation of alkaline phosphatase levels. All three patients experienced symptom relief within 7 days of voriconazole discontinuation, and the bone scintigraphy findings and alkaline phosphatase elevation were reversible.</div></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"10 3","pages":"Article 100179"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2451959625000095","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Voriconazole, the first-choice treatment for invasive aspergillosis, can induce periostitis. For unknown reasons, most reports on this rare side effect are in the field of organ transplantation, especially lung transplantation, and mostly from Western countries. However, in Asian countries, including Japan, the incidence of this complication may be underestimated. Herein, we report three Japanese patients who developed voriconazole-induced periostitis after lung transplantation. The patients’ initial symptoms were pain in the left shoulder, bilateral axillae, and left upper arm. The duration of voriconazole treatment before symptom onset ranged from 5 to 59 months. The diagnosis was confirmed by bone scintigraphy in two patients and computed tomography scan in one patient with or without elevation of alkaline phosphatase levels. All three patients experienced symptom relief within 7 days of voriconazole discontinuation, and the bone scintigraphy findings and alkaline phosphatase elevation were reversible.
肺移植后伏立康唑引起的骨膜炎:病例系列
伏立康唑是治疗侵袭性曲霉病的首选药物,可诱发骨膜炎。由于未知的原因,大多数关于这种罕见副作用的报道都是在器官移植领域,尤其是肺移植领域,而且大多来自西方国家。然而,在亚洲国家,包括日本,这种并发症的发生率可能被低估了。在此,我们报告了三名日本患者在肺移植后发生伏立康唑诱导的骨膜炎。患者最初的症状是左肩、双侧腋窝和左上臂疼痛。出现症状前伏立康唑治疗持续时间为5 ~ 59个月。两名患者的骨显像和一名患者的计算机断层扫描证实了诊断,有或没有碱性磷酸酶水平升高。3例患者均在停药7天内症状缓解,骨显像结果和碱性磷酸酶升高均可逆。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Transplantation Reports
Transplantation Reports Medicine-Transplantation
CiteScore
0.60
自引率
0.00%
发文量
24
审稿时长
101 days
期刊介绍: To provide to national and regional audiences experiences unique to them or confirming of broader concepts originating in large controlled trials. All aspects of organ, tissue and cell transplantation clinically and experimentally. Transplantation Reports will provide in-depth representation of emerging preclinical, impactful and clinical experiences. -Original basic or clinical science articles that represent initial limited experiences as preliminary reports. -Clinical trials of therapies previously well documented in large trials but now tested in limited, special, ethnic or clinically unique patient populations. -Case studies that confirm prior reports but have occurred in patients displaying unique clinical characteristics such as ethnicities or rarely associated co-morbidities. Transplantation Reports offers these benefits: -Fast and fair peer review -Rapid, article-based publication -Unrivalled visibility and exposure for your research -Immediate, free and permanent access to your paper on Science Direct -Immediately citable using the article DOI
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信